Lung cancer drug slashes patients’ risk of death by 51%
https://www.freethink.com/health/lung-cancer-drug
The FDA-approved lung cancer drug osimertinib (Tagrisso) reduces the risk of death by 51% for certain patients whose cancer is caught early, according to new trial data. The drug was approved in 2020 to treat non-small cell lung cancer that was caught before it had spread and after doctors had surgically removed what cancer they could from the lungs. The new results show that the drug can extend overall survival for these patients, providing them with the best chance of long-term survival.
sim
npub1sm…5yn0r
2023-07-09 20:49:38
in reply to naddr1qq…2l73
Author Public Key
npub1sm9xgupw9ejwsddflq8ll7773yzc0mjcsp5xypw4h4k6c7pgav9sn5yn0rPublished at
2023-07-09 20:49:38Event JSON
{
"id": "a9aa25b701e58ad4e1f8eadb9cdb438366038f6718bd543e8e22eb761940a08a",
"pubkey": "86ca64702e2e64e835a9f80ffffbde890587ee5880686205d5bd6dac7828eb0b",
"created_at": 1688928578,
"kind": 1,
"tags": [
[
"a",
"34550:86ca64702e2e64e835a9f80ffffbde890587ee5880686205d5bd6dac7828eb0b:Futurology"
],
[
"r",
"https://www.freethink.com/health/lung-cancer-drug"
],
[
"subject",
"Lung cancer drug slashes patients’ risk of death by 51%"
]
],
"content": "Lung cancer drug slashes patients’ risk of death by 51%\n\nhttps://www.freethink.com/health/lung-cancer-drug\n\nThe FDA-approved lung cancer drug osimertinib (Tagrisso) reduces the risk of death by 51% for certain patients whose cancer is caught early, according to new trial data. The drug was approved in 2020 to treat non-small cell lung cancer that was caught before it had spread and after doctors had surgically removed what cancer they could from the lungs. The new results show that the drug can extend overall survival for these patients, providing them with the best chance of long-term survival.",
"sig": "612f7be0f32c4012706f8fcffa4243807ad81523f27cce719821e346a9f0a9ddb4e10b624e4cadf67b265950ae247988ce9503bdc00abae87ac8baa013e96958"
}